Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Onc Now: Episode 24: What Will the Next Decade of HER2-Targeted Therapy Look Like?

35:58
 
Share
 

Manage episode 501790291 series 3412919
Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field.

Timestamps

00:00 – Introduction

02:50 – What initially drew Komal into oncology

04:45 – The future of breast cancer care

06:13 – Possibility of personalised treatments for patients

07:40 – Antibody-drug conjugates

09:30 – How we define HER2 status

14:40 – HER2-low disease

17:40 – Targeted therapy combinations

20:54 – Endocrine resistance

23:18 – The realities of implementing new therapies

28:40 – Promising initiatives on the horizon

31:30 – Komal's key takeaways

  continue reading

199 episodes

Artwork
iconShare
 
Manage episode 501790291 series 3412919
Content provided by EMJ. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EMJ or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field.

Timestamps

00:00 – Introduction

02:50 – What initially drew Komal into oncology

04:45 – The future of breast cancer care

06:13 – Possibility of personalised treatments for patients

07:40 – Antibody-drug conjugates

09:30 – How we define HER2 status

14:40 – HER2-low disease

17:40 – Targeted therapy combinations

20:54 – Endocrine resistance

23:18 – The realities of implementing new therapies

28:40 – Promising initiatives on the horizon

31:30 – Komal's key takeaways

  continue reading

199 episodes

सभी एपिसोड

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play